Grants and Contracts
| PrincipaI Investigator | Name of Award/Description of Study | Project Start | Project End | Awarded By | Total Value |
| Anas Al-Janadi | Phase 1/2 Relapsed or Refractory Diffuse Large B Cell Lymphoma | 1/5/2017 | 1/5/2020 | Incyte Pharmaceutical | Clinical Trial |
| Anas Al-Janadi | Prospective, Lognitudinal Non-Interventional study for patients with low risk Myelofibrosis | 2/2/2017 | 1/29/2022 | Incyte Pharmaceutical | Clinical Trial |
| Anas Al-Janadi | The National Myelodysplastic Syndromes (MDS) Study | 5/30/2017 | 2/28/2019 | NRG - NCI/NIH | Clinical Trial |
| Anas Al-Janadi | Phase 2/3 Replapsed or Refractory Multiple Myeloma | 8/1/2017 | 7/31/2022 | Millennium Pharmaceutical | Clinical Trial |
| Anas Al-Janadi | Phase 2 High Risk Myelodysplastic Syndrome | 8/15/2017 | 7/31/2022 | Helsinn HealthCare/MEI Pharma, INC | Clinical Trial |
| Anas Al-Janadi | Phase 2 Unresponsive Non-Muscle Invasive Bladder Cancer | 9/29/2017 | 9/28/2022 | NRG - NCI/NIH | Clinical Trial |
| Anas Al-Janadi | Phase 3 Newly Diagnosed Acute Myeloid Leukemia unfit for standard chemotherapy | 4/2/2018 | 4/30/2023 | Helsinn HealthCare/MEI Pharma, INC | Clinical Trial |
| Anas Al-Janadi | Phase 3 Newly Diagnosed Symptomatic Multiple Myeloma | 8/1/2018 | 2/28/2019 | NRG - NCI/NIH | Clinical Trial |
| Anthony Oliveri | Supporting MI Agriculture 2019-Implementing Respiratory Protection and Hazard Identification |
10/1/2018 | 9/30/2019 | State of MI | $19,999.00 |
| Danial Havilchek Gary Stein |
Ceftaroline and Levofloxacin for Community Acquired Bacterial Pneumonia | 2/1/2012 | 12/31/2021 | Forest Laboratories Inc | $70,704.84 |
| Elahe Crockett-Torabi | Research Education Program to increase diversity in health related research | 4/1/2016 | 3/31/2021 | National Inst of Health | $798,243.81 |
| Gary Stein Daniel Havilchek |
Safety and efficacy of Tigecycline in the Treatment of C. difficile associated diarrhea (CDAD) | 3/1/2011 | 12/31/2021 | Pfizer Pharmaceuticals | $46,080.00 |
| Boris Hrinczenko | Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subject | 4/20/2016 | 12/31/2018 | EMD Serono Inc | Clinical Trial |
| Boris Hrinczenko | Phase 3 Stage 3 Colon Cancer | 7/1/2016 | 6/30/2020 | NRG - NCI/NIH | Clinical Trial |
| Boris Hrinczenko | Phase 2 Esophageal Cancer | 8/26/2016 | 7/31/2019 | BIG Ten Cancer Consortium | Clinical Trial |
| Boris Hrinczenko | Phase 2 Study of MM-121 in Combination with Docetaxel or Pemetrexed versus Docetasel or Pemetrexed Alone in Patients with Herebulin Positive Locally Advanced or Metastatic Non-small cell lung | 5/1/2017 | 4/30/2021 | Merrimack Pharmaceuticals | Clinical Trial |
| Boris Hrinczenko | Phase 2 Non-small Cell Lung Cancer | 11/13/2017 | 11/30/2021 | BIG Ten Cancer Consortium | Clinical Trial |
| John Penner Park Weed Willis |
Coumadin aspirin reinfarction study (CARS) | 6/1/1993 | 12/31/2021 | Duke University | $13,585.00 |
| Ken Rosenman | OEC Exposure Code Systems Update | 10/1/2011 | 12/31/2018 | Assoc of Occupational & Environmental Clinics | $176,500.00 |
| Ken Rosenman | Expanded Program in Occupational Injury & Illness Surveillance | 7/1/2015 | 6/30/2020 | Centers for Disease Control & Prevention | $2,740,000.00 |
| Ken Rosenman | Worker Compensation Surveillance | 9/1/2016 | 8/31/2019 | National Inst of Health | $600,000.00 |
| Ken Rosenman | Worksite intervention to Mitigate Child Take Home Lead Exposure | 6/1/2018 | 5/31/2019 | MI Dept of Health & Human Services | $75,000.00 |
| Ken Rosenman | Evaluation of Silicosis, Asthma & COPD amount sand/gravel & Stone Surface Miners |
7/1/2018 | 12/31/2019 | Alpha Foundation for the Improvement of Mine Safety & Health Inc |
$250,000.00 |
| Ken Rosenman | Adult Blood Lead Epidemiology & Surveillance (ABLES) program | 10/1/2018 | 9/30/2019 | MI Dept of Health & Human Services | $44,400.00 |
| Maryann Tran | Methicillin-resistant Staphlococcus aureus | 12/14/2010 | 12/31/2021 | Roche Pharmaceuticals | $24,251.07 |
| Melissa Millerick May | A field based investigation of the generation of bioaerosol containing Porcine Epidemic Diarrhea virus (PEDv) during manure removals on swine farms in Michigan |
4/16/2015 | 8/31/2019 | Michigan Pork Producers Assoc | $10,500.00 |
| Melissa Millerick May | Improved method for identifying Causative Antigen in Hypersensitivity Pheumonitis |
12/1/2016 | 11/30/2021 | National Inst of Allergy & Infectious Diseases | $978,194.00 |
| Naveen Kakumanu | Multicenter multinational randomised parallel-group placebo controlled (double-blind) and active controlled (open) trial to compare the efficacy and safety of once weekly dosing of NNC |
4/9/2015 | 2/28/2019 | Novo Nordisk | $41,488.00 |
| Ralph Watson | Epigenomics of Hypertension in Monozygotic Twins & effect of salt intake |
4/1/2018 | 3/31/2019 | American Heart Assoc | $109,658.00 |
| Jatin Rana | Phase2 Metastatic or Advance Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma | 11/20/2017 | 11/30/2021 | BIG Ten Cancer Consortium | Clinical Trial |
| Diemante Tamkus | Phase 3 High Risk Hormone Receptor-Positive, HER2 Negative Breast Cancer | 6/1/2016 | 2/28/2019 | NRG - NCI/NIH | Clinical Trial |
| Diemante Tamkus | Phase 3 BRCA1/2, High Risk HER2 Negative Breast Cancer | 6/1/2016 | 2/28/2019 | NRG - NCI/NIH | Clinical Trial |
| Diemante Tamkus | 7/15/2016 | 8/31/2020 | Vertex Pharmaceutical | Clinical Trial | |
| Diemante Tamkus | Phase 2 Metastatic Hormone Receptor Positive Breast Cancer | 9/8/2016 | 7/31/2021 | BIG Ten Cancer Consortium | Clinical Trial |
| Diemante Tamkus | Molecular Analysis for Therapy Choice | 10/3/2016 | 2/28/2019 | NRG - NCI/NIH | Clinical Trial |
| Diemante Tamkus | Phase 3 Triple Negative Breast Cancer | 12/1/2016 | 12/31/2018 | Medivation, Inc and Astellas Pharma | Clinical Trial |
| Diemante Tamkus | Phase 3 Triple Receptor Negative Breast Cancer with>1cm residual invasive cancer or positive lymph nodes | 5/1/2017 | 12/31/2018 | NRG - NCI/NIH | Clinical Trial |
| Diemante Tamkus | Phase 3 Neoadjuvant Chemotherapy with Triple Negative Breast Cancer | 11/1/2017 | 1/31/2023 | NRG - NCI/NIH | Clinical Trial |
| Diemante Tamkus | Phase 1/2 Advance AR + Triple Negative Breast Cancer | 3/23/2018 | 3/31/2021 | BIG Ten Cancer Consortium | Clinical Trial |
| Diemante Tamkus | Phase 3 Evaluating the role of weight loss in adjuvant treatment of overweight/obese women with early breast cancer | 6/1/2018 | 5/31/2023 | NRG - NCI/NIH | Clinical Trial |
| Diemante Tamkus | Phase 2 Her 2 Negative Advance/Metastatic Breast Cancer | 7/3/2018 | 7/21/2023 | BIG Ten Cancer Consortium | Clinical Trial |
| Ved Gossain | The Global Hypopituitary control and complications study (HYPOCCS) | 5/1/2006 | 12/31/2021 | Eli Lilly & Co | $151,548.72 |